About Trivalent Therapeutics

Our Mission

Trivalent Therapeutics LLC is a Dallas-based intellectual property company dedicated to advancing novel pharmacological approaches to alcohol use disorder (AUD) — a condition affecting tens of millions of people yet served by only a handful of approved medications. Because naltrexone — the opioid-antagonist half of our combination — has been FDA-approved on its own for opioid use disorder (OUD) relapse prevention since 1984, our filed method claims also reach that indication as an adjacent, investigational one. The combination itself is untested there, and relapse after withdrawal remains the central unsolved clinical problem.

We believe the next generation of AUD therapy lies in the metabolic-reward axis. Our work centers on retatrutide, a triple agonist of the GLP-1, GIP, and glucagon receptors, and the methods by which it can reduce craving, relapse, and heavy alcohol consumption.

Our Approach

Rather than developing drugs in-house from end to end, Trivalent concentrates on what it does best: identifying differentiated mechanisms of action, securing robust patent protection around them, and partnering with pharmaceutical companies positioned to bring those methods through clinical development and to market.

This model lets clinical-stage partners build on a defensible foundation of intellectual property while accelerating the path from concept to patient.

The Science

Retatrutide's simultaneous engagement of three incretin pathways distinguishes it from earlier single- and dual-agonist agents such as semaglutide and tirzepatide. By modulating central reward signaling alongside metabolic effects, the molecule offers a uniquely broad mechanism for addressing the neurobiology of addiction — including in combination with established agents such as naltrexone.

The Naltrexone Combination

A central pillar of our portfolio pairs retatrutide with naltrexone, a well-established mu-opioid receptor antagonist used in addiction medicine. Naltrexone blunts the reinforcing reward that follows a drink by blocking mu-opioid receptors, while retatrutide reduces consumption drive through incretin signaling. The same receptor blockade is what makes naltrexone, as a single agent, an approved relapse-prevention therapy in opioid use disorder after medically supervised withdrawal; our filed method claims extend the combination to that indication as an adjacent, investigational one. There are no clinical data for the combination in any indication. Because the two agents act on non-overlapping mechanisms, the combination produces synergistic — greater-than-additive — reductions in craving, consumption, and relapse, and enables a dose-sparing regimen at sub-therapeutic doses of each agent. Explore the combination science →